Pro Feature
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moCompany
Accord Biopharma
NC - Raleigh
REGADENOSON (regadenoson) by Accord Biopharma is adenosine receptor agonists [moa]. Approved for adenosine receptor agonist [epc]. First approved in 2022.
Drug data last refreshed 20h ago
Adenosine Receptor Agonists
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Use of Stress-CMR Using Regadenoson and GE-267 in Adult Patients with Known or Suspected Coronary Artery Disease
A Study to Evaluate the Safety and Pharmacokinetics of Regadenoson in Pediatric Patients
Accuracy of an Echo-Stress Protocol Using Regadenoson With Speckle Tracking
Regadenoson for Acute Vasoreactivity Testing in Pulmonary Hypertension
A Phase II Trial of Regadenoson in Sickle Cell Anemia
Worked on REGADENOSON at Accord Biopharma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo